- Home
- BPTH vs TOVX Comparison
BPTH vs TOVX Comparison
Compare BPTH & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPTH
- TOVX
- Stock Information
- Founded
- BPTH 2007
- TOVX 2001
- Country
- BPTH United States
- TOVX United States
- Employees
- BPTH N/A
- TOVX N/A
- Industry
- BPTH Biotechnology: Pharmaceutical Preparations
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- BPTH Health Care
- TOVX Health Care
- Exchange
- BPTH Nasdaq
- TOVX Nasdaq
- Market Cap
- BPTH 5.0M
- TOVX 3.2M
- IPO Year
- BPTH N/A
- TOVX 2006
- Fundamental
- Price
- BPTH $1.09
- TOVX $1.73
- Analyst Decision
- BPTH Strong Buy
- TOVX Strong Buy
- Analyst Count
- BPTH 2
- TOVX 1
- Target Price
- BPTH $30.00
- TOVX $6.00
- AVG Volume (30 Days)
- BPTH 6.2M
- TOVX 1.0M
- Earning Date
- BPTH 11-15-2024
- TOVX 11-12-2024
- Dividend Yield
- BPTH N/A
- TOVX N/A
- EPS Growth
- BPTH N/A
- TOVX N/A
- EPS
- BPTH N/A
- TOVX N/A
- Revenue
- BPTH N/A
- TOVX N/A
- Revenue This Year
- BPTH N/A
- TOVX N/A
- Revenue Next Year
- BPTH N/A
- TOVX N/A
- P/E Ratio
- BPTH N/A
- TOVX N/A
- Revenue Growth
- BPTH N/A
- TOVX N/A
- 52 Week Low
- BPTH $0.59
- TOVX $1.14
- 52 Week High
- BPTH $12.00
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- BPTH 54.13
- TOVX 60.21
- Support Level
- BPTH $1.11
- TOVX $1.58
- Resistance Level
- BPTH $1.34
- TOVX $1.77
- Average True Range (ATR)
- BPTH 0.30
- TOVX 0.16
- MACD
- BPTH 0.02
- TOVX 0.06
- Stochastic Oscillator
- BPTH 16.36
- TOVX 62.77
About BPTH Bio-Path Holdings Inc.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.